Denali Therapeutics Inc. (DNLI) Share-based Payment Arrangement, Expense USD 2017 - 2024

Historical data

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Denali Therapeutics Inc. quarterly/annual Share-based Payment Arrangement, Expense history and growth rate from 2017 to 2024.
  • Denali Therapeutics Inc. Share-based Payment Arrangement, Expense for the quarter ending March 31, 2024 was $27.8 M, a 0.87% decline year-over-year.
  • Denali Therapeutics Inc. Share-based Payment Arrangement, Expense for the twelve months ending March 31, 2024 was $108 M, a 5.97% increase year-over-year.
  • Denali Therapeutics Inc. annual Share-based Payment Arrangement, Expense for 2023 was $108 M, a 8.27% increase from 2022.
  • Denali Therapeutics Inc. annual Share-based Payment Arrangement, Expense for 2022 was $99.8 M, a 17.1% increase from 2021.
  • Denali Therapeutics Inc. annual Share-based Payment Arrangement, Expense for 2021 was $85.2 M, a 69.3% increase from 2020.
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q1 2024 $108 M $27.8 M -$244 K -0.87% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-07
Q4 2023 $108 M $26 M +$802 K +3.18% Oct 1, 2023 Dec 31, 2023 10-K 2024-02-28
Q3 2023 $107 M $27.5 M +$2.88 M +11.7% Jul 1, 2023 Sep 30, 2023 10-Q 2023-11-07
Q2 2023 $104 M $26.6 M +$2.63 M +11% Apr 1, 2023 Jun 30, 2023 10-Q 2023-08-08
Q1 2023 $102 M $28.1 M +$1.94 M +7.42% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-07
Q4 2022 $99.8 M $25.2 M +$3.1 M +14% Oct 1, 2022 Dec 31, 2022 10-K 2024-02-28
Q3 2022 $96.7 M $24.6 M +$3.58 M +17.1% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-07
Q2 2022 $93.2 M $23.9 M +$2.8 M +13.2% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-08
Q1 2022 $90.4 M $26.1 M +$5.12 M +24.3% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-08
Q4 2021 $85.2 M $22.1 M +$8.26 M +59.7% Oct 1, 2021 Dec 31, 2021 10-K 2024-02-28
Q3 2021 $77 M $21 M +$7.75 M +58.5% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-03
Q2 2021 $69.2 M $21.1 M +$8.65 M +69.3% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-08
Q1 2021 $60.6 M $21 M +$10.2 M +95% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-05
Q4 2020 $50.4 M $13.8 M +$4.94 M +55.6% Oct 1, 2020 Dec 31, 2020 10-K 2023-02-27
Q3 2020 $45.4 M $13.3 M +$4.35 M +48.9% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-04
Q2 2020 $41.1 M $12.5 M -$1.23 M -8.97% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-04
Q1 2020 $42.3 M $10.8 M +$3.91 M +56.9% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-05
Q4 2019 $38.4 M $8.89 M +$3.24 M +57.4% Oct 1, 2019 Dec 31, 2019 10-K 2022-02-28
Q3 2019 $35.1 M $8.9 M +$3.39 M +61.5% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-05
Q2 2019 $31.7 M $13.7 M +$9 M +191% Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-07
Q1 2019 $22.7 M $6.87 M +$3.95 M +135% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-07
Q4 2018 $18.8 M $5.65 M +$4.19 M +288% Oct 1, 2018 Dec 31, 2018 10-K 2021-02-26
Q3 2018 $14.6 M $5.51 M +$4.38 M +388% Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-06
Q2 2018 $10.2 M $4.71 M +$3.65 M +345% Apr 1, 2018 Jun 30, 2018 10-Q 2019-08-06
Q1 2018 $6.57 M $2.93 M +$2.16 M +282% Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-08
Q4 2017 $4.41 M $1.46 M Oct 1, 2017 Dec 31, 2017 10-K 2020-02-27
Q3 2017 $1.13 M Jul 1, 2017 Sep 30, 2017 10-Q 2018-11-08
Q2 2017 $1.06 M Apr 1, 2017 Jun 30, 2017 10-Q 2018-08-09
Q1 2017 $765 K Jan 1, 2017 Mar 31, 2017 10-Q 2018-05-11
* An asterisk sign (*) next to the value indicates that the value is likely invalid.